These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 24552640)

  • 1. The pathophysiology and pharmacology of hepcidin.
    Ruchala P; Nemeth E
    Trends Pharmacol Sci; 2014 Mar; 35(3):155-61. PubMed ID: 24552640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Manipulation of the hepcidin pathway for therapeutic purposes.
    Fung E; Nemeth E
    Haematologica; 2013 Nov; 98(11):1667-76. PubMed ID: 24186312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepcidin and iron disorders: new biology and clinical approaches.
    Arezes J; Nemeth E
    Int J Lab Hematol; 2015 May; 37 Suppl 1():92-8. PubMed ID: 25976966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of hepcidin to treat iron deregulation: potential clinical applications.
    Blanchette NL; Manz DH; Torti FM; Torti SV
    Expert Rev Hematol; 2016; 9(2):169-86. PubMed ID: 26669208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepcidin.
    Ganz T
    Rinsho Ketsueki; 2016; 57(10):1913-1917. PubMed ID: 27725588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepcidin.
    Agarwal AK; Yee J
    Adv Chronic Kidney Dis; 2019 Jul; 26(4):298-305. PubMed ID: 31477260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders.
    Ganz T; Nemeth E
    Hematology Am Soc Hematol Educ Program; 2011; 2011():538-42. PubMed ID: 22160086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of the Iron Homeostatic Hormone Hepcidin.
    Sangkhae V; Nemeth E
    Adv Nutr; 2017 Jan; 8(1):126-136. PubMed ID: 28096133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of hepcidin and iron-overload disease.
    Lee PL; Beutler E
    Annu Rev Pathol; 2009; 4():489-515. PubMed ID: 19400694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulators of hepcidin expression.
    Roth MP; Meynard D; Coppin H
    Vitam Horm; 2019; 110():101-129. PubMed ID: 30798807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepcidin and iron homeostasis.
    Ganz T; Nemeth E
    Biochim Biophys Acta; 2012 Sep; 1823(9):1434-43. PubMed ID: 22306005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepcidin and Iron in Health and Disease.
    Nemeth E; Ganz T
    Annu Rev Med; 2023 Jan; 74():261-277. PubMed ID: 35905974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The molecular basis of iron overload disorders and iron-linked anemias.
    Kaplan J; Ward DM; De Domenico I
    Int J Hematol; 2011 Jan; 93(1):14-20. PubMed ID: 21210258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological Targeting of the Hepcidin/Ferroportin Axis.
    Sebastiani G; Wilkinson N; Pantopoulos K
    Front Pharmacol; 2016; 7():160. PubMed ID: 27445804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythropoietic regulators of iron metabolism.
    Ganz T
    Free Radic Biol Med; 2019 Mar; 133():69-74. PubMed ID: 29981834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepcidin and disorders of iron metabolism.
    Ganz T; Nemeth E
    Annu Rev Med; 2011; 62():347-60. PubMed ID: 20887198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia.
    Schmidt PJ; Toudjarska I; Sendamarai AK; Racie T; Milstein S; Bettencourt BR; Hettinger J; Bumcrot D; Fleming MD
    Blood; 2013 Feb; 121(7):1200-8. PubMed ID: 23223430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches.
    Schmidt PJ; Fleming MD
    Hematol Oncol Clin North Am; 2014 Apr; 28(2):387-401. PubMed ID: 24589273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepcidin-ferroportin axis in health and disease.
    Ginzburg YZ
    Vitam Horm; 2019; 110():17-45. PubMed ID: 30798811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New thiazolidinones reduce iron overload in mouse models of hereditary hemochromatosis and β-thalassemia.
    Liu J; Liu W; Liu Y; Miao Y; Guo Y; Song H; Wang F; Zhou H; Ganz T; Yan B; Liu S
    Haematologica; 2019 Sep; 104(9):1768-1781. PubMed ID: 30792208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.